Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Fujifilm, BD, PerkinElmer, OpGen, More

NEW YORK – Fujifilm said this week that it has completed its asset purchase of Inspirata's digital pathology business, effective Jan. 23. The Dynamyx digital pathology technology and the US employees who supported the business now are part of Fujifilm Healthcare Americas. Terms of the acquisition announced in December were not disclosed. The creation of the digital pathology division expands Fujifilm's Synapse Enterprise Imaging offering and enables pathology images to be digitized and integrated into a healthcare organization's electronic health record system, the company said. 

OpGen has regained compliance with Nasdaq’s minimum bid price requirement after enacting a 1-for-20 reverse stock split earlier this month, it disclosed in a document filed with the US Securities and Exchange Commission this week. In February 2022, the firm received notice that it was not in compliance with the rule as its stock had fallen below $1.00. OpGen originally had until Aug. 29, 2022, to regain compliance, but the deadline was extended to Feb. 28, 2023. From Jan. 5, 2023, through Jan. 19, 2023, OpGen’s stock closed at $1.00 per share or higher, allowing the company to regain compliance with the requirement. 

PerkinElmer said this week that its board of directors has declared a regular quarterly dividend of $.07 per share of common stock, payable May 12 to all shareholders of record as of April 21. 

Becton Dickinson said this week that its board of directors has declared a quarterly cash dividend of $.91 per share of common stock, to be paid on March 31 to stockholders of record as of March 10. In addition, the firm said the indicated annual dividend rate is $3.64 per share. 

T2 Biosystems announced preliminary financial results this week. For the recently completed fourth quarter, the firm had total revenue of $5.5 million, including product revenue of $2.2 million and research contribution revenue of $3.3 million. For the full year 2022, the Lexington, Massachusetts, company had total revenue of $22.3 million, including product revenue of $11.3 million and research contribution revenue of $11.0 million. T2 signed 51 T2Dx instrument contracts in the year, including 27 in the US and 24 outside the US. The firm exited 2022 with $11.9 million in cash, cash equivalents, and restricted cash. 

Dante Genomics said this week that its Dubai, United Arab Emirates-based lab has received ISO 15189 accreditation. The firm said the certification will help it bring clinical whole-genome sequencing to patients in the Middle East, Asia, and Africa. Dante recently partnered with Saudi Arabia's Al Farabi Medical Laboratories on clinical genomic testing. 

Novacyt this week issued an unaudited trading update reporting 2022 revenues of £21.0 million ($26.0 million), compared to £92.6 million for 2021, due to an expected decline in COVID-19 related sales. Full-year 2022 COVID revenues were £14.7 million and non-COVID revenues were £6.3 million, compared to 2021 revenues of £84.0 million and £8.6 million, respectively. The Paris, France, and Eastleigh, UK, firm ended the year with £87.0 million in cash. 

PreludeDx said this week that it has reached a deal with Medical Cost Containment Professionals to process out-of-network claims for PreludeDx's DCISionRT test, a risk assessment test for patients with ductal carcinoma in situ for predicting the potential benefit of radiation therapy. Patients of the more than 150,000 providers that are part of MCCP will now have access to the test. The technology underlying the DCISionRT test was licensed from the University of California, San Francisco. 

 In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.